Chris Tsopelas1, Richard Sutton. 1. Royal Adelaide Hospital, Nuclear Medicine Department, RAH Radiopharmacy, Adelaide, South Australia, Australia. ctsopelas@mail.rah.sa.gov.au
Abstract
UNLABELLED: Location of the sentinel lymph node in malignant melanoma and early breast cancer patients requires separate injections of radiocolloid and blue dye. These agents are administered at alternative times because of their different rates of transit. This study has elucidated why particular dyes are absorbed by the lymphatic system from an investigation of dye molecular structure as a function of protein binding ability. METHODS: A dye-protein binding assay was developed using size-exclusion chromatography and ultraviolet spectrophotometry and applied to a series of 20 sulfonic acid group-containing dyes. Radiochemical analyses were also used with 3 99mTc-labeled dyes to rationalize which functional groups are involved in the protein binding reaction. RESULTS: Methylene blue resulted in no protein affinity at 37 degrees C, whereas disulfonate dyes separated by 1 atom such as Patent blue or Indigo carmine gave <30% binding. Optimum protein binding (84%-100%) was achieved with those dyes containing at least 2 sulfonic acid groups separated by 2-6 atoms in their chemical structure. Seven symmetric tetrasulfonic acid azo dyes were examined, including Evans blue, to result in 59%-71% binding. CONCLUSION: Ionizable groups (sulfonic acids) that are present in the structure of dyes are directly involved in dye-protein binding. At the molecular level, there is a sulfonation reaction between sulfonic acid dyes and amino groups on the protein surface to form sulfonamide complexes. This reaction shows how the soluble dyes Evans blue and Patent blue are trapped in lymph after subdermal injection during the sentinel node biopsy procedure.
UNLABELLED: Location of the sentinel lymph node in malignant melanoma and early breast cancerpatients requires separate injections of radiocolloid and blue dye. These agents are administered at alternative times because of their different rates of transit. This study has elucidated why particular dyes are absorbed by the lymphatic system from an investigation of dye molecular structure as a function of protein binding ability. METHODS: A dye-protein binding assay was developed using size-exclusion chromatography and ultraviolet spectrophotometry and applied to a series of 20 sulfonic acid group-containing dyes. Radiochemical analyses were also used with 3 99mTc-labeled dyes to rationalize which functional groups are involved in the protein binding reaction. RESULTS:Methylene blue resulted in no protein affinity at 37 degrees C, whereas disulfonate dyes separated by 1 atom such as Patent blue or Indigo carmine gave <30% binding. Optimum protein binding (84%-100%) was achieved with those dyes containing at least 2 sulfonic acid groups separated by 2-6 atoms in their chemical structure. Seven symmetric tetrasulfonic acidazo dyes were examined, including Evans blue, to result in 59%-71% binding. CONCLUSION:Ionizable groups (sulfonic acids) that are present in the structure of dyes are directly involved in dye-protein binding. At the molecular level, there is a sulfonation reaction between sulfonic acid dyes and amino groups on the protein surface to form sulfonamide complexes. This reaction shows how the soluble dyes Evans blue and Patent blue are trapped in lymph after subdermal injection during the sentinel node biopsy procedure.
Authors: Annette H Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair J Cochran; Martin G Cook; Krzysztof T Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori Journal: Eur J Nucl Med Mol Imaging Date: 2009-10 Impact factor: 9.236
Authors: Metehan Gumus; Hatice Gumus; Sue E Jones; Peter A Jones; Ali R Sever; Jennifer Weeks Journal: Breast Care (Basel) Date: 2013-06 Impact factor: 2.860
Authors: Derrek A Heuveling; Gerard W M Visser; Mattijs de Groot; Johannes F de Boer; Marian Baclayon; Wouter H Roos; Gijs J L Wuite; C René Leemans; Remco de Bree; Guus A M S van Dongen Journal: Eur J Nucl Med Mol Imaging Date: 2012-02-17 Impact factor: 9.236
Authors: Eiichi Tanaka; Frederick Y Chen; Robert Flaumenhaft; Gwenda J Graham; Rita G Laurence; John V Frangioni Journal: J Thorac Cardiovasc Surg Date: 2009-07 Impact factor: 5.209